← Back to All US Stocks

Neuronetics, Inc. (STIM) Fundamental Analysis & AI Grade 2026

STIM Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001227636
Updated This Month • Analysis: May 7, 2026 • SEC Data: 2026-03-31
Combined AI Grade
C
78% Confidence
N/A
C
78% Conf
Pending
Analysis scheduled

📊 STIM Key Takeaways

Revenue: $34.5M
Net Margin: -31.3%
Free Cash Flow: $-9.6M
Current Ratio: 1.67x
Debt/Equity: 4.62x
EPS: $-0.16
AI Grade: C with 78% confidence
Neuronetics, Inc. (STIM) receives a C fundamental grade with 78% confidence from our AI analysis based on SEC 10-K filings. With revenue of $34.5M, net profit margin of -31.3%, and return on equity (ROE) of -81.3%, Neuronetics, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete STIM stock analysis for 2026.

Is Neuronetics, Inc. (STIM) a Good Investment?

Claude

Neuronetics exhibits exceptional revenue growth (+99.2% YoY) with healthy gross margins (46.9%), but fundamentals are severely compromised by negative operating cash flow (-$9.4M), high leverage (4.62x Debt/Equity), and inability to cover interest expenses. At current burn rates with only $13.2M cash, financial distress risk is substantial despite improving loss trajectory.

Neuronetics, Inc. Key Strengths (STIM)

Claude
  • + Exceptional top-line growth at 99.2% YoY demonstrates strong market demand
  • + Solid gross margin of 46.9% indicates pricing power and viable unit economics
  • + Improving loss per share trend (+57.2% YoY) suggests operational path toward profitability

STIM Stock Risks: Neuronetics, Inc. Investment Risks

Claude
  • ! Negative operating cash flow (-$9.4M) and negative free cash flow (-$9.6M) are unsustainable
  • ! Extreme leverage of 4.62x Debt/Equity with only $13.3M stockholders equity and $61.3M long-term debt creates financial distress risk
  • ! Negative interest coverage (-4.0x) indicates inability to service debt from operations; cash runway approximately 1.4 years at current burn rate
  • ! Operating margin of -26.1% shows growth is not yet profitable despite rapid scaling
  • ! High insider activity (24 Form 4 filings in 90 days) warrants scrutiny regarding confidence

Key Metrics to Watch

Claude
  • * Time to operating profitability and path to positive operating margins
  • * Operating cash flow trajectory and time to positive FCF generation
  • * Debt refinancing needs and debt maturity schedule relative to cash position
  • * Gross margin sustainability as revenue scales and operating leverage improvement

Neuronetics, Inc. (STIM) Financial Metrics & Key Ratios

Revenue
$34.5M
Net Income
$-10.8M
EPS (Diluted)
$-0.16
Free Cash Flow
$-9.6M
Total Assets
$125.4M
Cash Position
$13.2M

💡 AI Analyst Insight

Neuronetics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.

STIM Profit Margin, ROE & Profitability Analysis

Gross Margin 46.9%
Operating Margin -26.1%
Net Margin -31.3%
ROE -81.3%
ROA -8.6%
FCF Margin -27.9%

STIM vs Healthcare Sector: How Neuronetics, Inc. Compares

How Neuronetics, Inc. compares to Healthcare sector averages

Net Margin
STIM -31.3%
vs
Sector Avg 12.0%
STIM Sector
ROE
STIM -81.3%
vs
Sector Avg 15.0%
STIM Sector
Current Ratio
STIM 1.7x
vs
Sector Avg 2.0x
STIM Sector
Debt/Equity
STIM 4.6x
vs
Sector Avg 0.6x
STIM Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Neuronetics, Inc. Stock Overvalued? STIM Valuation Analysis 2026

Based on fundamental analysis, Neuronetics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.

Return on Equity
-81.3%
Sector avg: 15%
Net Profit Margin
-31.3%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
4.62x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Neuronetics, Inc. Balance Sheet: STIM Debt, Cash & Liquidity

Current Ratio
1.67x
Quick Ratio
1.50x
Debt/Equity
4.62x
Debt/Assets
86.4%
Interest Coverage
-3.97x
Long-term Debt
$61.3M

STIM Revenue & Earnings Growth: 5-Year Financial Trend

STIM 5-year financial data: Year 2021: Revenue $62.7M, Net Income -$29.0M, EPS $-1.58. Year 2022: Revenue $65.2M, Net Income -$27.5M, EPS $-1.46. Year 2023: Revenue $71.3M, Net Income -$31.2M, EPS $-1.22. Year 2024: Revenue $74.9M, Net Income -$37.2M, EPS $-1.38. Year 2025: Revenue $149.2M, Net Income -$30.2M, EPS $-1.05.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Neuronetics, Inc.'s revenue has grown significantly by 138% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.05 indicates the company is currently unprofitable.

STIM Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-27.9%
Free cash flow / Revenue

STIM Quarterly Earnings & Performance

Quarterly financial performance data for Neuronetics, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $32.0M -$10.8M $-0.16
Q3 2025 $18.5M -$9.0M $-0.13
Q2 2025 $16.5M -$9.8M $-0.15
Q1 2025 $17.4M -$7.9M $-0.21
Q3 2024 $17.9M -$4.9M $-0.33
Q2 2024 $16.5M -$4.9M $-0.17
Q1 2024 $15.5M -$7.9M $-0.27
Q3 2023 $16.5M -$4.9M $-0.28

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

Neuronetics, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$9.4M
Cash generated from operations
Capital Expenditures
$197.0K
Investment in assets
Dividends
None
No dividend program

STIM SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Neuronetics, Inc. (CIK: 0001227636)

📋 Recent SEC Filings

Date Form Document Action
May 29, 2026 4 xslF345X06/ownership.xml View →
May 29, 2026 4 xslF345X06/ownership.xml View →
May 29, 2026 4 xslF345X06/ownership.xml View →
May 29, 2026 4 xslF345X06/ownership.xml View →
May 29, 2026 4 xslF345X06/ownership.xml View →

Frequently Asked Questions about STIM

What is the AI rating for STIM?

Neuronetics, Inc. (STIM) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.

What are STIM's key strengths?

Claude: Exceptional top-line growth at 99.2% YoY demonstrates strong market demand. Solid gross margin of 46.9% indicates pricing power and viable unit economics.

What are the risks of investing in STIM?

Claude: Negative operating cash flow (-$9.4M) and negative free cash flow (-$9.6M) are unsustainable. Extreme leverage of 4.62x Debt/Equity with only $13.3M stockholders equity and $61.3M long-term debt creates financial distress risk.

What is STIM's revenue and growth?

Neuronetics, Inc. reported revenue of $34.5M.

Does STIM pay dividends?

Neuronetics, Inc. does not currently pay dividends.

Where can I find STIM SEC filings?

Official SEC filings for Neuronetics, Inc. (CIK: 0001227636) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is STIM's EPS?

Neuronetics, Inc. has a diluted EPS of $-0.16.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is STIM's fundamental grade?

Based on our AI fundamental analysis in May 2026, Neuronetics, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is STIM stock overvalued or undervalued?

Valuation metrics for STIM: ROE of -81.3% (sector avg: 15%), net margin of -31.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is STIM's AI grade for 2026?

Our dual AI analysis gives Neuronetics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is STIM's free cash flow?

Neuronetics, Inc.'s operating cash flow is $-9.4M, with capital expenditures of $197.0K. FCF margin is -27.9%.

How does STIM compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -31.3% (avg: 12%), ROE -81.3% (avg: 15%), current ratio 1.67 (avg: 2).

Is Neuronetics, Inc. carrying too much debt?

STIM has a debt-to-equity ratio of 4.62x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.67 suggests adequate short-term liquidity.

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 7, 2026 | Data as of: 2026-03-31 | Powered by Claude AI